Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice.
OBJECTIVE
Evaluation of an outpatient 17 α-hydroxyprogesterone caproate (17P) administration programme.


METHODS
A retrospective analysis of data collected from patients with a history of preterm birth (PTB) and current singleton gestation enrolled between 16.0 and 20.9 weeks' gestational age (GA) for weekly outpatient 17P administration and nursing assessment between 7/2004 and 12/2007 was conducted (n=3139).


RESULTS
The population was mostly white (50.3%), 18-35 years old (77.7%), and married (67.0%). Median GA at 17P initiation and stop was 17.4 (16.0, 20.9) weeks and 35.1 (18.6, 37.4) weeks. Mean injections per patient were 16.5±4.9, at an interval of 7.2 days. Median GA at delivery was 37.3 (18.6, 44.0) weeks. Rate of recurrent spontaneous PTB was 29.8%, with 15.5% and 7.0% with PTB at <35 and <32 weeks.


CONCLUSIONS
This represents the largest cohort reported to date of patients prescribed 17P therapy in clinical practice to prevent recurrent spontaneous PTB.
Rebarber
Andrei
A
Maternal Fetal Medicine Associates, New York, NY 10029, USA. arebarber@mfmnyc.com
Fox
Nathan S
NS
Klauser
Chad K
CK
Istwan
Niki B
NB
Rhea
Debbie J
DJ
Stanziano
Gary J
GJ
Saltzman
Daniel H
DH
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000293:Adolescent; D000328:Adult; D015331:Cohort Studies; D005260:Female; D006699:Home Care Services; D006801:Humans; D006908:Hydroxyprogesterones / Q000008:administration & dosage*; D007273:Injections, Intramuscular; D007752:Obstetric Labor, Premature / Q000188:drug therapy*; D010353:Patient Education as Topic; D017060:Patient Satisfaction; D011247:Pregnancy; D047928:Premature Birth / Q000517:prevention & control*; D011295:Prenatal Care; D011372:Progestins / Q000008:administration & dosage*; D055815:Young Adult
D006908:Hydroxyprogesterones; D011372:Progestins; D000077713:17 alpha-Hydroxyprogesterone Caproate